Invertix | $1,977,831 | (Jun 2, 2026)
XCENA | $135,000,000 | (Jun 2, 2026)
Kubera Health | $6,500,000 | (May 29, 2026)
Certified by Founder
Lodge
Curevo Vaccine
start up
United States
- Bothell, Washington
- 19/03/2025
- Series B
- $110,000,000
Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent herpes zoster, commonly known as shingles. Our goal with a new herpes zoster vaccine is to improve the patient experience and, ultimately, overall vaccination rates, by developing amezosvatein as a vaccine with non-inferior efficacy combined with clinically-meaningful improvements in reactogenicity when compared to Shingrix.
- Industry Biotechnology Research
- Website https://curevovaccine.com/
- LinkedIn https://www.linkedin.com/company/curevovaccine/
Related People
George SimeonFounder
United States -
Greater Seattle Area
Strategic Alliances, Global Commercialisation, M&A, Joint-Ventures, Organization Building
Balance between: Strategic Thinking - Creative Problem Solving - 'Hands-on' Execution
Countable Labs | $26,000,000 | (May 29, 2026)
Solstice | $21,000,000 | (May 29, 2026)
Rep AI | $6,200,000 | (May 29, 2026)
Psilera | $8,800,000 | (May 29, 2026)
Reactor | $59,000,000 | (May 29, 2026)
MokN | $15,000,000 | (May 29, 2026)
Volt Harbor Inc. | $2,000,000 | (May 29, 2026)
Crimson | $2,500,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)